Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:3963
Name thyroid gland carcinoma
Definition A thyroid gland cancer that has_material_basis_in epithelial cells.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer thyroid cancer thyroid gland carcinoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
RET C634W Sorafenib thyroid gland carcinoma sensitive detail...
RET C634W Ponatinib thyroid gland carcinoma sensitive detail...
RET M918T Ponatinib thyroid gland carcinoma sensitive detail...
RET C634W Cabozantinib thyroid gland carcinoma sensitive detail...
BRAF V600E PIK3CA H1047R Dabrafenib + Everolimus + Trametinib thyroid gland carcinoma predicted - sensitive detail...
BRAF V600E PIK3CA H1047R Everolimus thyroid gland carcinoma resistant detail...
BRAF V600E PIK3CA H1047R Dabrafenib + Trametinib thyroid gland carcinoma resistant detail...
CD274 positive Pembrolizumab thyroid gland carcinoma predicted - sensitive detail...
BRAF V600E Dabrafenib thyroid gland carcinoma predicted - sensitive detail...
BRAF V600E Dabrafenib + Trametinib thyroid gland carcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01208051 Phase Ib/II Cediranib + Lenalidomide Cediranib Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer Completed USA | CAN 0
NCT01655719 Phase II Pioglitazone Pioglitazone in Thyroid Cancers Completed USA 0
NCT02428712 Phase Ib/II PLX8394 A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors Active, not recruiting USA 0
NCT02628067 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Recruiting USA | ITA | FRA | ESP | DEU | CAN | AUS 16
NCT02834013 Phase 0 Ipilimumab + Nivolumab Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Active, not recruiting USA 1
NCT03181100 Phase II Atezolizumab + Cobimetinib Atezolizumab + Bevacizumab Atezolizumab + Nab-paclitaxel Atezolizumab + Cobimetinib + Vemurafenib Atezolizumab + Paclitaxel Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer Active, not recruiting USA 0
NCT04171622 Phase II Lenvatinib + Pembrolizumab Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer Recruiting USA 0
NCT04619316 Phase II Dabrafenib + Trametinib Trametinib Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition (ERRITI) Recruiting DEU 0
NCT04759911 Phase II Selpercatinib Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer Recruiting USA 0
NCT05786924 Phase I BDTX-4933 A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers Recruiting USA 0
NCT05852223 Phase II Pembrolizumab Pembrolizumab in High-risk Thyroid Cancer (NePenThe) Recruiting ITA 0
NCT05949424 FDA approved Lenvatinib Olaparib Pazopanib Palbociclib Sunitinib OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults (OPTI-DOSE) Not yet recruiting 1